Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07587905

Effects of Calamansi on Blood Glucose and Insulin Levels

Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Calamansi Powder Capsule Supplementation

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL.
  • Aged between 18-30 years, both male and female
  • Body Mass Index (BMI) between 18.5 and 22.9 kg/m²
  • No diseases affecting blood sugar levels, such as liver or pancreatic diseases

Exclusion criteria

  • Pregnant or breastfeeding women
  • Regular smokers
  • Regular alcohol consumers
  • Individuals with a history of allergies to citrus fruits or citrus-derived ingredients
  • Individuals taking medications that affect glucose metabolism and fat distribution in the body, including steroids, protease inhibitors, and psychiatric medications. These refer to drugs that act on the central nervous system and may affect blood sugar levels or energy metabolism, such as antidepressants, antipsychotics, and mood stabilizers.

Treatment and study plan

MMC powder capsule

Other

Each capsule contains MMC powder for 500 mg

Calamansi powder capsule

Dietary Supplement

Each capsule contains calamansi powder for 500 mg

Primary outcomes

  1. Concentrations of blood glucose

    Time frame: At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption

    Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit

  2. Concentrations of blood insulin

    Time frame: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption

    Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit

  3. Concentrations of blood malondialdehyde

    Time frame: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption

    Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit

Secondary outcomes

  1. Levels of heart rate variability

    Time frame: At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes

    Heart rate variability were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in ms (milliseconds) and ms2 (millisecond squared) unit

Study contacts

Contact information is provided by the study sponsor or research team.

Kulwara Poolpol, Ph.D.

CONTACT

[email protected]

6638103147

Piyapong Prasertsri, Ph.D.

CONTACT

[email protected]

6638103166

Sponsors and collaborators

Lead sponsor

Burapha University

Other

Registry information

Official study title

The Effects of Calamansi (Citrus x Macrocarpa Bunge) Supplementation on Blood Glucose and Insulin Levels in Healthy Volunteers

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
May 14, 2026
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.